Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PEOPLE - Changes at SynCardia Systems:

This article was originally published in Clinica

Executive Summary

SynCardia Systems' plans to launch the CardioWest Total Artificial Heart in the US have gone a step further with the appointment of Michael Quinn, chairman and CEO of Cardiogenesis, as vice-chairman of the board. SynCardia chairman and CEO Dr Marvin Slepian said the move addresses the "need for leadership and a profound understanding of the challenges of commercialising advanced cardiovascular therapies". The appointment is part of the company's "necessary restructuring ... as it transitions from a research organisation to a commercially viable company", added the co-founder of the Tucson, Arizona-based company. Cardiogenesis, of Foothill Ranch, California, makes the Holmium: YAG laser and related accessories for transmyocardial revascularisation (TMR) therapy and percutaneous myocardial channelling.

You may also be interested in...

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 

QUOTED. 30 November 2020. David Hoffmeister.

A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts